Dr Aguirre on Daraxonrasib Bringing RAS-Targeted Therapy to Pancreatic CancerByAndrew AguirreNovember 17th 2026Andrew Aguirre, MD, PhD, explained how daraxonrasib, a molecular glue RAS inhibitor, nearly doubled overall survival in previously treated pancreatic cancer.